![]() To find out how Development Reimagined can support you, your organisation or Government to respond to COVID-19 in a sustainable way please email the team at thanks go to Rosie Flowers-Wanjie, Osaru Omosigho, David Tinashe Nyagweta and Jing Cai for their work on the graphics and collecting/analysing the underlying data and this accompanying article. Have a read, check out the graphics and numbers below, and do let us know what you conclude and what you’d like us to find out next time! This rich and informative data behind this analysis is available below. As institutions expected to be assisting countries in meeting global public goods, our analysis provides clear evidence that significant reform is needed in such institutions, now. Not only is there significant economic incentive now for vaccine production on the continent, it will avoid the effects of hoarding, while securing future access to new innovations, such as mRNA vaccines, that is efficient and sustainable and tackles future health inequities.Īnd finally, as we write this, the IMF and World Bank Spring meetings are getting started. Whatever the decision, a key lesson is also in relation to local manufacturing. While stringent lockdowns have their own challenges, our analysis suggests that African countries cannot rely on vaccines only – they will need to continue to have some types of social distancing measures in place for the long-term. In North America, highest supply in March 2021 dwarfed Africa’s highest total by almost 100 million doses.įor African countries, these inequities in vaccine availability create a dangerous context, especially with global public health measures waning and new COVID-19 waves expected to emerge. For example, over 50% of Europe’s vaccine doses were received in summer 2021. For other regions, the highest levels of vaccine delivery were met much earlier and sustained throughout the year. Supply of vaccines across African countries has been sporadic, with the majority of doses received towards the end of 2021. Simultaneously they have also gained from the popularity of these vaccines around the world – for example, Pfizer and AstraZeneca account for over 50% of Oceania’s vaccine supply.Īnother significant marker for Africa is vaccine delivery. ![]() These regions have benefitted from their own vaccine spending on North American and European produced vaccines such as Pfizer and Moderna. This is similarly true for North America and Europe. This means that of the 134 billion USD spent on vaccine procurement in Asia, over 50% was spent within the Asian continent, with concomitant benefits in terms of revenues and jobs. Meanwhile, African countries are dependent on others for the procurement of a very wide variety of vaccines. In contrast, Asian countries overwhelming rely on Asian-produced vaccines such as Sinovac and Sinopharm – which together make up more than 50% of Asia’s vaccine supply. For example, only three African countries – Kenya, Egypt and Tunisia – are represented in the top 20 countries that received vaccination donations – and all are middle-income. However, African countries also represent a small percentage of global vaccine donations. ![]() Considering many African countries are low-income countries it is reasonable to assume expenditure would be less than continents with a higher number of middle and high-income countries. However, in vaccine expenditure, African countries represent only 5% of the global total spent on vaccine procurement. The low doses are not for trying! Vaccine campaigns have been launched and are working – 67% of vaccine supplies on the continent have been used already. With such few doses, even with younger populations than some other regions, a vaccine-led COVID-19 management strategy is highly risky. In sharp contrast, African countries have acquired just 0.5 vaccines per person. Hoarding in some regions is clearly happening. In terms of population, Asian countries as a group have acquired 2 vaccines per person, North America 3 vaccines per person, and Europe 4.1 vaccines per person. However, African countries account for only 5% of these doses, whilst the majority have been acquired by Asia, Europe and North America. Since the beginning of the pandemic, there have been 12.7 billion vaccines acquired globally. ![]() Is it realistic for African countries to focus on vaccine-led management strategies? This question is what this month’s infographic tries to answer. However, vaccine supply for African countries has been very slow. Our infographics have continually demonstrated the continued efforts of African governments to vaccinate their populations. As COVID-19 social distancing interventions continue to be relaxed in many countries in favour of vaccine-led strategies, while new variants of COVID-19 continue to emerge, the way forward for global COVID-19 management seems very unclear. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |